Abstract
Treatment of patients with unresectable stage Ilia and IIIB non-small cell lung cancer with conventional radiation therapy has resulted in poor local control, a high rate of systemic failure, and 5-year survival of less than 10%. Recent modification in radiation treatment planning, dose delivery, and fractionization has demonstrated significantly improved median and 2- year survival, comparable in some trials to that achieved with induction chemotherapy followed by radiation. Current trials focus on combining systemic therapy with dose-intense radiation therapy to improve with local and systemic control.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 423-428 |
| Number of pages | 6 |
| Journal | Seminars in Oncology |
| Volume | 24 |
| Issue number | 4 |
| State | Published - 1997 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
Cite this
}
Radiation therapy in the management of patients with unresectable stage IIIA and IIIB non-small cell lung cancer. / Wagner Jr., Henry.
In: Seminars in Oncology, Vol. 24, No. 4, 1997, p. 423-428.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Radiation therapy in the management of patients with unresectable stage IIIA and IIIB non-small cell lung cancer
AU - Wagner Jr., Henry
PY - 1997
Y1 - 1997
N2 - Treatment of patients with unresectable stage Ilia and IIIB non-small cell lung cancer with conventional radiation therapy has resulted in poor local control, a high rate of systemic failure, and 5-year survival of less than 10%. Recent modification in radiation treatment planning, dose delivery, and fractionization has demonstrated significantly improved median and 2- year survival, comparable in some trials to that achieved with induction chemotherapy followed by radiation. Current trials focus on combining systemic therapy with dose-intense radiation therapy to improve with local and systemic control.
AB - Treatment of patients with unresectable stage Ilia and IIIB non-small cell lung cancer with conventional radiation therapy has resulted in poor local control, a high rate of systemic failure, and 5-year survival of less than 10%. Recent modification in radiation treatment planning, dose delivery, and fractionization has demonstrated significantly improved median and 2- year survival, comparable in some trials to that achieved with induction chemotherapy followed by radiation. Current trials focus on combining systemic therapy with dose-intense radiation therapy to improve with local and systemic control.
UR - http://www.scopus.com/inward/record.url?scp=0030786471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030786471&partnerID=8YFLogxK
M3 - Review article
VL - 24
SP - 423
EP - 428
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 4
ER -